Published in Eur J Immunol on March 01, 1990
Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A (1994) 3.77
Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J Clin Invest (2005) 3.15
T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med (1994) 2.31
Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo. J Clin Invest (2006) 2.00
A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock. Infect Immun (1995) 1.99
T cell activation causes diarrhea by increasing intestinal permeability and inhibiting epithelial Na+/K+-ATPase. J Clin Invest (2002) 1.74
Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology (2010) 1.57
Expression of a tumor necrosis factor alpha transgene in murine pancreatic beta cells results in severe and permanent insulitis without evolution towards diabetes. J Exp Med (1992) 1.46
Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med (1997) 1.33
Distinction of the memory B cell response to cognate antigen versus bystander inflammatory signals. J Exp Med (2009) 1.25
Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc Natl Acad Sci U S A (1991) 1.22
Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice. Immunology (1993) 1.13
p53 mediates TNF-induced epithelial cell apoptosis in IBD. Am J Pathol (2012) 1.07
Inter-mouse strain differences in the in vivo anti-CD3 induced cytokine release. Clin Exp Immunol (1991) 1.05
Mechanisms and functional implications of intestinal barrier defects. Dig Dis (2009) 1.04
Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo. J Clin Invest (1994) 1.01
Current imaging strategies in rheumatoid arthritis. Am J Nucl Med Mol Imaging (2012) 0.94
New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity. J Neurol Sci (2008) 0.93
T cell receptor (TCR) engagement leads to activation-induced splicing of tumor necrosis factor (TNF) nuclear pre-mRNA. J Exp Med (1998) 0.91
In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants. J Clin Invest (1994) 0.90
Partial and transient modulation of the CD3-T-cell receptor complex, elicited by low-dose regimens of monoclonal anti-CD3, is sufficient to induce disease remission in non-obese diabetic mice. Immunology (2010) 0.89
Regulation of endothelial VCAM-1 expression in murine cardiac grafts. Expression of allograft endothelial VCAM-1 can be manipulated with antagonist of IFN-alpha or IL-4 and is not required for allograft rejection. Am J Pathol (1995) 0.87
Differential outcome of tolerance induction in naive versus activated Theiler's virus epitope-specific CD8+ cytotoxic T cells. J Virol (2007) 0.87
Functional characterization of N297A, a murine surrogate for low-Fc binding anti-human CD3 antibodies. Immunol Invest (2009) 0.86
Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients. Mediators Inflamm (2000) 0.83
Acute inflammation alters bicarbonate transport in mouse ileum. J Physiol (2007) 0.83
Inhibition of skin xenograft rejection by depleting T-cell receptor alpha beta-bearing cells without T-cell receptor gamma delta-bearing cells or natural killer cells by monoclonal antibody. Immunology (1994) 0.83
Prevention of anti-T-cell receptor alpha beta monoclonal antibody-induced side-effects by treatment with cyclosporin A without interference of monoclonal antibody-induced immunosuppression in mice. Immunology (1995) 0.82
Lethal effect of CD3-specific antibody in mice deficient in TGF-beta1 by uncontrolled flu-like syndrome. J Immunol (2009) 0.82
An anti-CD3 monoclonal antibody protects mice against a lethal infection with Listeria monocytogenes through induction of endogenous cytokines. Infect Immun (1993) 0.81
Regulation of endothelial VCAM-1 expression in murine cardiac grafts. Roles for TNF and IL4. Am J Pathol (1995) 0.80
Anti-CD3ε mAb improves thymic architecture and prevents autoimmune manifestations in a mouse model of Omenn syndrome: therapeutic implications. Blood (2012) 0.80
Limitations in immunotherapy with CD3 antibodies: comment on the article by Drs. Chatenoud and Bach. Rev Diabet Stud (2006) 0.78
Effects of anti-CD3 monoclonal antibodies on functional activity of lymphocytes: studies in vivo and in vitro. Clin Exp Immunol (1995) 0.77
In vitro T cell unresponsiveness following low-dose injection of anti-CD3 MoAb. Clin Exp Immunol (1996) 0.77
Combination anti-CD2 and anti-CD3 monoclonal antibodies induce tolerance while altering interleukin-2, interleukin-4, tumor necrosis factor, and transforming growth factor-beta production. Ann Surg (1993) 0.77
Characterization of a surrogate murine antibody to model anti-human CD3 therapies. MAbs (2013) 0.77
In vivo T cell activation induces the formation of CD209(+) PDL-2(+) dendritic cells. PLoS One (2013) 0.77
Beyond Ussing's chambers: contemporary thoughts on integration of transepithelial transport. Am J Physiol Cell Physiol (2015) 0.76
Teplizumab therapy for type 1 diabetes. Expert Opin Biol Ther (2010) 0.76
Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons. Islets (2013) 0.76
Major histocompatibility complex class II- fetal skin dendritic cells are potent accessory cells of polyclonal T-cell responses. Immunology (2000) 0.76
T-cell repopulation following neonatal injection of non-obese diabetic (NOD) mice with anti-T-cell antibodies. Immunology (1992) 0.75
In vivo T-cell activation by a monoclonal αCD3ε antibody induces preterm labor and birth. Am J Reprod Immunol (2016) 0.75
Differential regulation by phorbol myristate acetate of IFN-gamma and IL-4 expression in anti-CD3 stimulated mouse spleen cells. Immunology (1992) 0.75
Interleukin-6 inhibits apoptosis of exocrine gland tissues under inflammatory conditions. Cytokine (2015) 0.75
Non-mitogenic anti-CD3F(ab')2 monoclonal antibody: a novel approach to control herpetic stromal keratitis. Invest Ophthalmol Vis Sci (2008) 0.75
Approach to withdrawal from tacrolimus in a fully allogeneic murine skin graft model. Immunology (1999) 0.75
Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging multiple therapeutic targets. MAbs (2017) 0.75
Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity (1995) 10.65
Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci (2003) 10.44
Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity (1996) 8.27
Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature (1996) 8.02
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med (2001) 6.22
In vivo specific antigen recognition by rosette forming cells. Nature (1970) 4.78
In vitro evaluation of immunosuppressive drugs. Nature (1969) 4.70
Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells. J Exp Med (1987) 4.38
Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A (1994) 3.77
Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet (1997) 3.68
Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med (2001) 3.56
Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med (1995) 3.41
Detection of circulating immune complexes in human sera by simplified assays with polyethylene glycol. J Immunol Methods (1977) 3.24
Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev (1999) 3.19
Appearance of T-cell markers in bone marrow rosette-forming cells after incubation with thymosin, a thymic hormone. Proc Natl Acad Sci U S A (1971) 3.13
In vitro rosette inhibition by antihuman antilymphocyte serum. Correlation with skin graft prolongation in subhuman primates. Transplantation (1969) 3.12
CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol (1997) 2.89
Dexamethasone in bronchiolitis: a randomised controlled trial. Lancet (1996) 2.81
Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat Genet (1999) 2.79
Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guérin infection and a sibling with clinical tuberculosis. J Clin Invest (1997) 2.76
Overexpression of natural killer T cells protects Valpha14- Jalpha281 transgenic nonobese diabetic mice against diabetes. J Exp Med (1998) 2.75
T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice. J Exp Med (1989) 2.51
Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Eur J Immunol (1996) 2.43
The key role of nucleosomes in lupus. Arthritis Rheum (1999) 2.26
A sequential model for peptide binding and transport by the transporters associated with antigen processing. Immunity (1994) 2.26
A new in vitro test evaluating anti-lymphocyte serum potency. Transplant Proc (1969) 2.21
Studies on thymus products. II. Demonstration and characterization of a circulating thymic hormone. Immunology (1973) 2.17
Prognosis of patients with nonmalignant chronic intestinal failure receiving long-term home parenteral nutrition. Gastroenterology (1995) 2.16
Anti-glomerular-basement-membrane disease after lithotripsy. Lancet (1990) 2.11
Recurrent mutations in a single exon encoding the evolutionarily conserved olfactomedin-homology domain of TIGR in familial open-angle glaucoma. Hum Mol Genet (1997) 2.08
Postpartum coma. Lancet (1998) 2.07
TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol (1999) 2.05
Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index. Gut (1981) 2.00
Relation between tumor necrosis factor-alpha and granulocyte elastase-alpha 1-proteinase inhibitor complexes in the plasma of patients with cystic fibrosis. Am Rev Respir Dis (1989) 1.99
Factors affecting morbidity, mortality, and survival in patients undergoing Ivor Lewis esophagogastrectomy. Ann Surg (2000) 1.98
Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res (1997) 1.94
Studies on thymus products. IV. Absence of serum 'thymic activity' in adult NZB and (NZB x NZW) F1 mice. Clin Exp Immunol (1973) 1.93
Isolation, biochemical characteristics, and biological activity of a circulating thymic hormone in the mouse and in the human. Ann N Y Acad Sci (1975) 1.89
Establishment and characterization of a murine hybridoma secreting monoclonal anti-DNA autoantibody. J Immunol (1980) 1.88
Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur J Immunol (1988) 1.87
Evaluation of T-cells and thymic serum factors in man using the rosette technique. Transplant Rev (1973) 1.87
Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss syndrome--62 patients. J Rheumatol (1993) 1.86
Role of K(V)LQT1 in cyclic adenosine monophosphate-mediated Cl(-) secretion in human airway epithelia. Am J Respir Cell Mol Biol (2000) 1.85
Endocarditis associated with ANCA. Clin Exp Rheumatol (1994) 1.85
Transfer of symptomatic peanut allergy to the recipient of a combined liver-and-kidney transplant. N Engl J Med (1997) 1.83
Deficit of suppressor T cells in active multiple sclerosis. Lancet (1980) 1.83
Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med (1992) 1.82
The use of monoclonal anti-T cell antibodies to study T cell imbalances in human diseases. Clin Exp Immunol (1981) 1.82
Peanut agglutinin. I. A new tool for studying T lymphocyte subpopulations. J Immunol (1978) 1.80
Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2001) 1.79
Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol (1991) 1.78
A monoclonal anti-DNA antibody also binds to cell-surface protein(s). Proc Natl Acad Sci U S A (1984) 1.75
A gene for hereditary paroxysmal cerebellar ataxia maps to chromosome 19p. Ann Neurol (1995) 1.74
Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol (2001) 1.73
Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma. J Autoimmun (1991) 1.71
Prognostic factors in acute renal failure due to sepsis. Results of a prospective multicentre study. The French Study Group on Acute Renal Failure. Nephrol Dial Transplant (1996) 1.68
Systemic lupus erythematosus. Morphologic correlations with immunologic and clinical data at the time of biopsy. Am J Med (1978) 1.67
Poly(ADP-ribose) polymerase alleles in French Caucasians are associated neither with lupus nor with primary antiphospholipid syndrome. GRAID Research Group. Group for Research on Auto-Immune Disorders. Arthritis Rheum (1999) 1.67
Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum Mol Genet (1997) 1.65
Thymus dependency of rosette-forming cells: evidence for a circulating thymic hormone. Transplant Proc (1972) 1.63
Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus. J Clin Invest (1992) 1.63
Antigen recognition by T lymphocytes. II. Similar effects of azathioprine, antilymphocyte serum, and anti-theta serum on rosette-forming lymphocytes in normal and neonatally thymectomized mice. Cell Immunol (1972) 1.62
Gut mucosal mast cells. Origin, traffic, and differentiation. J Exp Med (1984) 1.61
Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes (1990) 1.57
The peptide-binding motif for the human transporter associated with antigen processing. J Exp Med (1995) 1.56
Intravenous immunoglobulin therapy for prevention of infection in high-risk premature infants: report of a multicenter, double-blind study. Pediatrics (1991) 1.55
Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus: correlation with serum antinucleosome antibody titers and absence of clear association with disease activity. Arthritis Rheum (1997) 1.55
Mature mainstream TCR alpha beta+CD4+ thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mouse. J Immunol (1998) 1.55
The rheumatoid rosette. A diagnostic test unifying seropositive and seronegative rheumatoid arthritis. Am J Med (1970) 1.55
Control of fetal survival in CBA x DBA/2 mice by lymphokine therapy. J Reprod Fertil (1990) 1.54
Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant (1992) 1.53
In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation (1990) 1.53
Early affect of adult thymectomy. Nat New Biol (1971) 1.53
Improvement of diabetic control and acceptability of a three-injection insulin regimen in diabetic adolescents. A multicenter controlled study. Diabetes Care (1993) 1.52
Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum (2000) 1.52
Renal prognosis in Alport's and related syndromes: influence of the mode of inheritance. Nephrol Dial Transplant (1989) 1.48
Necrotizing crescentic glomerulonephritis without significant immune deposits: a clinical and serological study. Q J Med (1993) 1.48
Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med (1988) 1.47
Autosomal dominant polycystic kidney disease with primary hyperaldosteronism. Nephrol Dial Transplant (1992) 1.46
Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty-acid synthase. Biol Chem Hoppe Seyler (1986) 1.45
Regulation of CTLA-4 expression during T cell activation. J Immunol (1996) 1.44
European experience of bone-marrow transplantation for severe combined immunodeficiency. Lancet (1990) 1.44
Binding of autologous erythrocytes to immature T-cells. Proc Natl Acad Sci U S A (1975) 1.43
Evaluation of T cell subsets in myasthenia gravis using anti-T cell monoclonal antibodies. Clin Exp Immunol (1981) 1.42
Thymic hormone-containing cells. Characterization and localization of serum thymic factor in young mouse thymus studied by monoclonal antibodies. J Exp Med (1982) 1.42
The amiloride-inhibitable Na+ conductance is reduced by the cystic fibrosis transmembrane conductance regulator in normal but not in cystic fibrosis airways. J Clin Invest (1998) 1.42
[Pefloxacin as a first-line treatment for nephrotic syndrome in minimal glomerular lesions in the adult. Multicenter study of 32 patients]. Nephrologie (1997) 1.41
The nurse's role in a team conference. Nurs Manage (1990) 1.40
Purinergic inhibition of the epithelial Na+ transport via hydrolysis of PIP2. FASEB J (2004) 1.40
Characterization of facteur thymique sérique (FTS) in the thymus. I. Fixation of anti-FTS antibodies on thymic reticulo-epithelial cells. Clin Exp Immunol (1980) 1.40
Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. Kidney Int (1995) 1.40
Cyclosporin and autoimmune disease. Lancet (1991) 1.39
[Periarteritis nodosa in a dental prosthetist]. Presse Med (1994) 1.39
[ICU patients and days of intensive care: A mathematical model optimizing the consequences of ICU unit function, intensive care and continual monitoring on incurred supplementary costs]. Ann Fr Anesth Reanim (2013) 1.39